Biocon Limited will Integrate Biocon Biologics Limited

News Desk, News Nation 360 : Biocon Limited, an innovation-driven global biopharmaceuticals company, announced a strategic corporate move to completely integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary of Biocon Limited, subject to all necessary clearances. To facilitate a seamless merger, Biocon Limited has formed a Governance Council chaired by Kiran Mazumdar-Shaw, as well as a Transition and Merger Management Committee led by Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Biologics Limited. A Strategy Committee was established in May 2025 by Biocon Limited, which explored alternatives such as IPOs and mergers for Biocon Biologics, recommending the total integration of the company through the purchase of minority interests to enhance value through strategic grouping and simplification. Biocon acquires the stakes of Serum Institute, Tata Capital, and Activ Pine in Biologics through a share swap ratio of 70.28 Biocon shares for every 100 shares of Biologics at ₹405.78, with a total valuation of $5.5B for the latter. The remaining stake of Viatris is priced at $815 million, of which $400 million is in cash, with the remaining $415 million via a share swap ratio of 61.70 Biocon shares for every 100 shares of Biologics, as validated by EY. Biocon would issue an equity infusion of ₹4,500 crores through QIP for the cash component, pending approvals. This is aimed for completion by March 31, 2026, with a global-scale presence in Diabetes, Oncology, and Immunology—I40% of their total pharmaceuticals business—to make Biocon the only player with biosimilar insulin and GLP-1 generics for the 'diabesity' patient universe. Siddharth Mittal and Shreehas Tambe remain as the firm's CEOS until completion, with Tambe as the subsequent CEO & MD, and Kedar Upadhye as the CFO of the new firm. Commenting on the corporate action, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, stated that the merger of Biocon Biologics Limited with Biocon Limited marks the next step in their journey. Strategically, Biocon will be one of the few businesses delivering both biosimilars and generics on a global basis. As the only firm that offers biosimilar insulins and generic GLP1 peptides, Biocon is well-positioned to meet the demands of diabetic patients. Together with their integrated oncology and immunology portfolios, this delivers a unique offering that addresses the world's most pressing healthcare needs.

Pic - Courtesy